Biodexa shares surge 20.83% after-hours following enrollment of first European patients in pivotal Phase 3 Serenta trial for FAP.

Biodexa Pharmaceuticals Plc (BDRX) surged 20.83% in after-hours trading following the announcement that it enrolled the first European patients into its pivotal Phase 3 Serenta trial for fibrous dysplasia (FAP). This milestone, reported by GlobeNewswire four days prior, marked progress in the company’s clinical development timeline, with the first European patient expected in Q4 2025. Earlier updates, including the activation of the first European trial site and approval of the Clinical Trial Application (CTA) in Europe, further underscored the trial’s advancement. The $7 billion estimated addressable market in the U.S. and Europe for FAP treatments also highlighted the trial’s commercial potential. These developments collectively reinforced investor confidence in BDRX’s pipeline, driving the post-market rally.